COYA · Coya Therapeutics, Inc.

Summary

Coya Therapeutics, Inc. disclosed its fiscal year 2025 financial results, reporting collaboration revenue of $7.9 million, net loss of $21.2 million, R&D expenses of $16.7 million, and cash and cash equivalents of $46.8 million as of December 31, 2025. The company highlighted clinical progress on COYA 302 for ALS and FTD, scientific publications, a U.S. patent issuance, and $34.1 million in financings extending cash runway into 2H 2027.

Key takeaways

• Cash and cash equivalents of $46.8 million as of December 31, 2025
• Collaboration revenue of $7.9 million for FY2025 vs $3.6 million for FY2024
• Net loss of $21.2 million for FY2025 vs $14.9 million for FY2024
• R&D expenses of $16.7 million for FY2025 vs $11.9 million for FY2024
• Launched ALSTARS Phase 2 trial for COYA 302 in ALS at ~25 U.S. and Canada sites
• FDA IND acceptance for COYA 302 in FTD; $23.0 million public offering and $11.1 million private placement